MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
24 Janvier 2024 - 1:15PM
Business Wire
- New patent would extend coverage and expand potential value
of MAIA’s telomere-targeting platform globally
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the
“Company”), a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer, today announced that the World
Intellectual Property Organization (WIPO) has published MAIA’s
global Patent Cooperation Treaty (PCT) application titled
“Dinucleotides and Their Use in Treating Cancer.” These compounds
are key next-generation telomere-targeting agents, an important
extension of MAIA’s innovative cancer treatment platform.
The international patent application covers potential cancer
therapies using dinucleotide compounds that target telomeres in
cancer cells, and methods for using the dinucleotide compounds to
treat cancers alone or before administration with checkpoint
inhibitors (CPIs). The new dinucleotides disclosed in the patent
application are telomere-targeting molecules, such as THIO
fragments or other THIO analogues.
The PCT system streamlines the process for obtaining patent
protection globally. Under the PCT, applicants can seek patent
protection in a large number of countries.
“This new IP would expand the value of our telomere-targeting
compounds as first-in-class cancer treatments in regions around the
world and provide patent coverage through 2043,” said Vlad Vitoc,
M.D., MAIA’s Chairman and Chief Executive Officer. “Previous
preclinical studies of several of our second-generation
telomere-targeting agents have shown highly significant anti-cancer
efficacy in multiple in vivo and in vitro models. Importantly, this
new coverage would further cement our robust and transformational
cancer treatment franchise.”
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class
investigational telomere-targeting agent currently in clinical
development to evaluate its activity in Non-Small Cell Lung Cancer
(NSCLC). Telomeres, along with the enzyme telomerase, play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. The modified nucleotide
6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent
telomeric DNA modification, DNA damage responses, and selective
cancer cell death. THIO-damaged telomeric fragments accumulate in
cytosolic micronuclei and activates both innate (cGAS/STING) and
adaptive (T-cell) immune responses. The sequential treatment with
THIO followed by PD-(L)1 inhibitors resulted in profound and
persistent tumor regression in advanced, in vivo cancer models by
induction of cancer type–specific immune memory. THIO is presently
developed as a second or later line of treatment for NSCLC for
patients that have progressed beyond the standard-of-care regimen
of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124751468/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024